within Pharmacolibrary.Drugs.ATC.N;

model N05AX11
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 2.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.03333333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.011,
    k12             = 2.5,
    k21             = 2.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AX11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Zotepine is an atypical antipsychotic drug primarily used for the treatment of schizophrenia. It acts mainly as an antagonist of dopamine D2 and serotonin 5-HT2A receptors, and is approved in Japan and some European countries, but is not approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Pailla, SR, et al., &amp; Dyawanapelly, S (2022). Brain-Targeted Intranasal Delivery of Zotepine Microemulsion: Pharmacokinetics and Pharmacodynamics. <i>Pharmaceutics</i> 14(5) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14050978\">10.3390/pharmaceutics14050978</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35631564/\">https://pubmed.ncbi.nlm.nih.gov/35631564</a></p></li><li><p>Tanaka, O, et al., &amp; Kaneko, S (1998). Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects. <i>Therapeutic drug monitoring</i> 20(1) 117–119. DOI:<a href=\"https://doi.org/10.1097/00007691-199802000-00021\">10.1097/00007691-199802000-00021</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9485566/\">https://pubmed.ncbi.nlm.nih.gov/9485566</a></p></li><li><p>Tirumalesh, C, et al., &amp; Banala, N (2020). Enhanced Pharmacokinetic Activity of Zotepine via Nanostructured Lipid Carrier System in Wistar Rats for Oral Application. <i>Pharmaceutical nanotechnology</i> 8(2) 148–160. DOI:<a href=\"https://doi.org/10.2174/2211738508666200225113359\">10.2174/2211738508666200225113359</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32096755/\">https://pubmed.ncbi.nlm.nih.gov/32096755</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AX11;
